Caldolor (Ibuprofen) Patent Expiration, LOE Window & CMS Spending
Caldolor (Ibuprofen) by Apotex: FDA Orange Book LOE 2032-03-16, 19 AB generics, $491K 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Apotex |
| FDA Application & Pathway | N022348 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2032-03-16 |
| Orange Book Patents (*PED Extensions) | 10 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 19 |
| 2024 CMS Total Public Spend | $491K |
| 2024 Medicare Part D Spend | $10K |
| 2024 Medicaid Spend | $481K |
| Reported Wholesale Price Change (CA SB 17) | 7 WAC filings (max 32.6% 2-yr change) |